Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.66 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007395 | 1.00 | UBE2T (0.66) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL3919004 | 0.84 | UBE2T (0.61) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL226465 | 0.83 | UBE2T (0.70) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL19372016 | 0.83 | UBE2T (0.70) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL1903062 | 0.82 | UBE2T (0.54) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL14835424 | 0.81 | SMN1; SMN2 (0.67) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| Bromide SCHEMBL7601035 | 0.81 | UBE2T (0.68) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL16397518 | 0.79 | UBE2T (0.66) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL322456 | 0.79 | UBE2T (0.66) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL244156 | 0.79 | UBE2T (0.66) | UBE2TASIC3MAPTSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3384066-B1 | METHOD FOR MONITORING THE TOTAL AMOUNT OF SULPHUR CONTAINING COMPOUNDS IN A METAL PLATING BATH | ATOTECH DEUTSCHLAND GMBH & CO KG (DE) | 2023-02-08 | — | — | EP | claimed |
| CN-115198256-A | Reducing solution for electroless copper plating of polyimide film and preparation method and application thereof | 上海天承化学有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-3384066-A1 | METHOD FOR MONITORING THE TOTAL AMOUNT OF SULPHUR CONTAINING COMPOUNDS IN A METAL PLATING BATH | ATOTECH Deutschland GmbH (DE) | 2018-10-10 | — | — | EP | claimed |
| CN-108291304-A | Method for monitoring the total amount of sulfur-containing compound in metal plating bath | 德国艾托特克公司 | 2018-07-17 | — | — | CN | claimed |
| WO-2017093481-A1 | METHOD FOR MONITORING THE TOTAL AMOUNT OF SULPHUR CONTAINING COMPOUNDS IN A METAL PLATING BATH | ATOTECH DEUTSCHLAND GMBH (DE) | 2017-06-08 | — | — | WO | claimed |
| CN-106632139-A | New method for synthesizing benzothiazole-2-formaldehyde and derivative thereof | 青岛科技大学 | 2017-05-10 | — | — | CN | claimed |
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | claimed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| CN-102887973-A | Preparation method of white fluorescent powder containing europium terbium beryllium polymer | UNIV TAIYUAN TECHNOLOGY | 2013-01-23 | — | — | CN | claimed |
| CN-102827599-A | Preparation method of red-green-blue blended white light phosphor | UNIV TAIYUAN TECHNOLOGY | 2012-12-19 | — | — | CN | claimed |
| US-7989472-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | claimed |
| WO-2010138833-A1 | SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2010-12-02 | — | — | WO | claimed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | claimed |
| EP-2001472-A2 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck and Co., Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007111864-A2 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-10-04 | — | — | WO | claimed |
| US-5750558-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | claimed |
| WO-1997041100-A1 | IMINOXY DERIVATIVES OF INDOLE AND INDENE COMPOUNDS AS INHIBITORS OF PROSTAGLANDIN BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1997-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | UBE2T 4126/4885ASIC3 1333/4885MAPT 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.